發送短信 : Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC

__    __   __   __   ______    __   __    ______  
\ \\ / //  \ \\/ // |      \\  \ \\/ //  /_   _// 
 \ \/ //    \ ` //  |  --  //   \ ` //   `-| |,-  
  \  //      | ||   |  --  \\    | ||      | ||   
   \//       |_||   |______//    |_||      |_||   
    `        `-`'   `------`     `-`'      `-`'